Wellgistics Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain(TM) Manufacturer-to-Patient Blockchain-Enabled Tracking & Dispensing Platform for Prescription Drug Market

Rhea-AI Summary

DataVault AI (NASDAQ: DVLT) and Wellgistics Health (NASDAQ: WGRX) entered a SAAS smart‑contract services agreement to develop PharmacyChain™, a manufacturer‑to‑patient blockchain tracking and dispensing platform targeting the $639 billion prescription drug market. The companies expect to finalize a profit‑sharing license in Q4 2025 and begin beta testing in H1 2026. DataVault AI cites issued U.S. patents dated April 16, 2024; June 25, 2024; and September 24, 2024 that it says cover blockchain, token‑driven data monetization and related IP. Management cites early inbound interest from manufacturers, pharmacists and insurers and describes plans for opt‑in biometric/diagnostic data and utility token monetization to enable new revenue streams.

Positive

• Signed SAAS development agreement between DVLT and WGRX
• Profit‑sharing license planned for Q4 2025
• Beta testing scheduled for H1 2026
• Claims of issued U.S. patents dated Apr 16, 2024, Jun 25, 2024, Sep 24, 2024
• Targets the $639 billion prescription drug market

Negative

• Profit‑sharing commercial terms not finalized until Q4 2025

Insights

Technology & Pharma Partnerships Analyst

A technology partnership to build a blockchain-enabled pharmacy tracking platform; pilot in the first half of 2026 with licensing details by Q4 2025.

The agreement pairs Wellgistics and DataVault AI to develop a manufacturer-to-patient smart-contract platform called PharmacyChain that targets the $639 billion prescription drug market. The business mechanism ties DataVault's patented data-exchange and tokenization IP to Wellgistics' distribution and hub fulfillment capabilities under a SAAS model, with a profit-sharing license to be finalized in Q4 2025 and beta testing expected in the first half of 2026.

Key dependencies and risks include successful technical integration between distributed ledger smart contracts and existing pharmacy workflows, regulatory and privacy consent for any biometric or diagnostic opt-in data, and converting early inbound interest into contracted customers; no revenue figures or commercial commitments are disclosed yet. Monitor the finalized profit-sharing terms in Q4 2025, the scope and partners in the beta program in the first half of 2026, and any regulatory or privacy clarifications tied to patient data use.

Powered by DataVault AI's High-Performance Computing & Information Exchange, Data Monetization for Traditional and Compound Pharmacies is Set to Become a Reality in the $639 Billion Prescription Drug Market, with Beta Testing Expected in First Half of 2026

Tampa, Florida and Philadelphia, Pennsylvania--(Newsfile Corp. - October 27, 2025) - Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that it has entered into a software as a service (SAAS) agreement with DataVault AI, Inc. (NASDAQ: DVLT) ("DataVault"), a pioneering technology company leading the way in AI data experience, valuation, and monetization, to begin the development of manufacturer-to-patient blockchain-enabled smart contracts ("PharmacyChain™") being designed to optimize Wellgistics' proprietary technology and physical infrastructure for the prescription drug industry. The companies expect to finalize the related profit-sharing license agreement in the fourth quarter of 2025, once all various potential revenue streams stemming from the partnership are identified and valued.

"In just the last few days, we have already received significant inbound interest from manufacturers, pharmacists and insurers who see the significant benefit in being able to reliably close the loop on prescriptions reaching pharmacies, pharmacies rapidly qualifying them for optimized insurance reimbursement and physicians receiving confirmation that patients actually receive their prescribed pharmaceutical regimens," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics. "We are making the integration of smart contracts a central pillar for our growth strategy going forward, allowing us to differentiate ourselves in the traditional pharmaceutical distribution and compound pharmacy spaces. We expect PharmacyChain to allow us to gain market share in the markets we are already in, as well as expand into new markets. Beta testing for PharmacyChain is expected to begin in the first half of 2026."

DataVault AI's Web 3.0 platform provides a proprietary IP and unique value proposition within the pharmaceutical distribution, pharmaceutical manufacturer and compound pharmacy spaces. The patent protected technology, enabled by breakthrough smart contracts, will allow pharmacies to securely and seamlessly receive and transfer data that will allow pharmacists to more easily make appropriate drug dispending decisions for the benefit of patients and insurers.

Patents that cover DataVault AI's blockchain and secure token driven data scoring, valuation, visualization and monetization on its patented Information Data Exchange® include, but are not limited to:

• U.S. Patent 12,100,025 entitled "Platform for Management of User Data," issued on September 24, 2024;
• U.S. Patent 11,960,622 entitled "Blockchain and secure token driven data scoring, valuation, visualization and monetization," issued on April 16, 2024;
• U.S. Patent 12,020,787 entitled "Triggered Responses to Real-time Electroencephalography," issued on June 25, 2024.

PharmacyChain is also expected to allow manufacturers to better understand their key constituents, physicians and patients, in order to make more personalized sales and marketing campaigns, as well as potentially expand upon the recent trend of direct-to-consumer cash sales. As part of Wellgistics' desire to help improve patient outcomes, it also intends to ultimately include diagnostic and biometric data, on an opt-in basis, to help further empower healthcare professionals and patients with data-driven recommendations based on gold-standard best practices from leading physicians who leverage the power of biomarker and biometric data to help optimize health outcomes for their patients.

"We are excited to assist Wellgistics in developing new additive revenue streams within the $639 billion prescription drug market," said Nathaniel Bradley, President & CEO of DataVault AI. "Wellgistics has positioned themselves at the intersection of physical and technology infrastructure in the pharmacy business. Our DataVault AI team will develop Digital Twins of pharmaceutical logistics, delivery systems and patients. Utility tokens will ensure that every medicine you are prescribed will also be accompanied by recommendations to optimize its use for your body by tailoring lifestyle and nutritional recommendations based upon your own personal health profile, on a consented 'opt-in' basis. The objective is to align prescribed medicines with increasingly commonplace wellness regimens, rooted in sound science and personal biomarker and biometric data obtained from the increasing use of wearable devices, which have demonstrated improved outcomes in well controlled studies. Previously this was an overwhelming task, however with our technology we can make this commonplace in healthcare's emerging high performance, data-driven era."

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ: WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

For more information, visit www.wellgisticshealth.com.

About DataVault AI Inc.

DataVault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI's technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Wellgistics Health Media & Investor Contact

Media:
media@wellgisticshealth.com
Investor Relations:
IR@wellgisticshealth.com

Wellgistics Health Investor Relations Contact
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

DataVault AI Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

DataVault AI Media Contact:
marketing@dvlt.ai

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272032

FAQ

What did DataVault AI (DVLT) announce with Wellgistics (WGRX) on October 27, 2025?

They announced a SAAS agreement to develop PharmacyChain™, a blockchain smart‑contract platform for prescription tracking and dispensing.

When will PharmacyChain beta testing begin for DVLT and WGRX?

Beta testing is expected to begin in the first half of 2026.

Has DataVault AI (DVLT) finalized licensing revenue terms with Wellgistics (WGRX)?

No; the companies expect to finalize a profit‑sharing license in Q4 2025.

Which patents did DataVault AI cite in the DVLT and WGRX announcement?

U.S. patents issued on Apr 16, 2024, Jun 25, 2024, and Sep 24, 2024 covering blockchain and data monetization.

What market size do DVLT and WGRX target with PharmacyChain?

They target the prescription drug market, cited at approximately $639 billion.